Exact Sciences Corporation (EXAS)
Automate Your Wheel Strategy on EXAS
With Tiblio's Option Bot, you can configure your own wheel strategy including EXAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXAS
- Rev/Share 16.2845
- Book/Share 13.2167
- PB 7.657
- Debt/Equity 1.008
- CurrentRatio 2.7226
- ROIC -0.1838
- MktCap 19175143847.0
- FreeCF/Share 1.3055
- PFCF 77.6061
- PE -19.4139
- Debt/Assets 0.4274
- DivYield 0
- ROE -0.4039
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EXAS | Mizuho | -- | Outperform | -- | $60 | April 10, 2025 |
| Initiation | EXAS | RBC Capital Mkts | -- | Sector Perform | -- | $52 | March 13, 2025 |
| Initiation | EXAS | Barclays | -- | Overweight | -- | $70 | Jan. 23, 2025 |
| Initiation | EXAS | Wells Fargo | -- | Overweight | -- | $75 | Aug. 28, 2024 |
News
Top 2 Health Care Stocks You May Want To Dump This Month
Published: December 02, 2025 by: Benzinga
Sentiment: Negative
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Read More
EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) to Abbott Laboratories for $105.00 per share in cash.
Read More
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Exact Sciences Corporation (“Exact Sciences” or the “Company”) (Nasdaq – EXAS) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the acquisition of the Company by Abbott (NYSE - ABT) for $105.00 per common share in cash, representing a total equity value of approximately $21 billion.
Read More
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More
Published: November 20, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes turned lower Thursday afternoon, reversing early gains as a rally powered by Nvidia's (NVDA) blockbuster earnings after the bell Wednesday faded. The Dow Jones Industrial Average slid 0.7%, the S&P 500 dropped 0.9%, and tech-heavy Nasdaq fell 1.1%.
Read More
Shareholder Alert: The Ademi Firm investigates whether Exact Sciences Corporation is obtaining a Fair Price for its Public Shareholders
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Nov. 20, 2025 /PRNewswire/ -- The Ademi Firm is investigating Exact Sciences (NASDAQ: EXAS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Abbott. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
Published: November 20, 2025 by: Proactive Investors
Sentiment: Positive
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.
Read More
EXAS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Exact Sciences Corporation is Fair to Shareholders
Published: November 20, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Exact Sciences Corporation (NASDAQ: EXAS) to Abbott for $105.00 per common share in cash is fair to Exact Sciences shareholders. Halper Sadeh encourages Exact Sciences shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns wh.
Read More
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories
Published: November 19, 2025 by: Investors Business Daily
Sentiment: Positive
Exact Sciences stock catapulted Wednesday amid rumors Abbott Laboratories is nearing a deal to buy the cancer-finding specialist.
Read More
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Published: November 19, 2025 by: Reuters
Sentiment: Positive
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
Read More
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Exact Sciences Corporation ( EXAS ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. I think we're good to go here.
Read More
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Exact Sciences (EXAS) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
Read More
Earnings Estimates Rising for Exact Sciences (EXAS): Will It Gain?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Exact Sciences (EXAS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Exact Sciences (EXAS) and EssilorLuxottica Unsponsored ADR (ESLOY) have performed compared to their sector so far this year.
Read More
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
5 Growth Stocks to Strengthen Your Portfolio in Q4 After a Fabulous Q3
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
After a stellar Q3 for Wall Street, five growth picks - MU, WDAY, EXAS, EVR, and CDE - stand out with rising earnings estimates.
Read More
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Read More
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Exact Sciences (EXAS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EXAS crossed above the 20-day moving average, suggesting a short-term bullish trend.
Read More
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Healthmine and Exact Sciences partner to increase colorectal cancer screening rates through at-home testing and health plan incentives.
Read More
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Read More
Should You Continue to Hold EXAS Stock in Your Portfolio?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Read More
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
Published: August 22, 2025 by: Business Wire
Sentiment: Neutral
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.
Read More
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Read More
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Top 3 Health Care Stocks That Are Preparing To Pump This Month
Published: August 11, 2025 by: Benzinga
Sentiment: Positive
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Read More
About Exact Sciences Corporation (EXAS)
- IPO Date 2001-02-01
- Website https://www.exactsciences.com
- Industry Medical - Diagnostics & Research
- CEO Kevin T. Conroy
- Employees 6900